Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
141
-
Total 13F shares, excl. options
-
70.8M
-
Shares change
-
+4.42M
-
Total reported value, excl. options
-
$1.74B
-
Value change
-
+$98.3M
-
Put/Call ratio
-
0.95
-
Number of buys
-
85
-
Number of sells
-
-56
-
Price
-
$24.49
Significant Holders of CG Oncology, Inc. - Common Stock (CGON) as of Q1 2025
168 filings reported holding CGON - CG Oncology, Inc. - Common Stock as of Q1 2025.
CG Oncology, Inc. - Common Stock (CGON) has 141 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70.8M shares
of 76.6M outstanding shares and own 92.42% of the company stock.
Largest 10 shareholders include Decheng Capital LLC (6.37M shares), VANGUARD GROUP INC (5.84M shares), BlackRock, Inc. (4.36M shares), TCG Crossover Management, LLC (3.67M shares), BRAIDWELL LP (3.28M shares), Kynam Capital Management, LP (2.61M shares), FMR LLC (2.55M shares), ORBIMED ADVISORS LLC (2.47M shares), MARSHALL WACE, LLP (2.42M shares), and Foresite Capital Management VI LLC (2.22M shares).
This table shows the top 141 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.